DOCSLIB.ORG

Pharmacokinetics Uses and Administration Adverse Effects And

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmacokinetics Uses and Administration Adverse Effects And Gadopentetic Acid/Gadoversetamide 1587 ble for those receiving medium- or low-risk agents, parti­ has paramagnetic properties and is used as a magnetic cularly patients aged 65 years or older. resonance contrast medium (p. 1580.1). It distributes Adverse Effects and Precautions M RA As for Gadopentetic Acid, p. 1586.2 and p. 1586.2, 1. Perazella A Rodby . Gadolinium-induced nephrogenic systemic mainly into extracellular fluid, but does not cross the blood­ fibrosis in patients with kidney disease. Am J Med 2007; 120: 561-2. brain barrier, and is used in imaging of cranial and spinal respectively. 2. Health Canada. Gadolinium-containing contrast agents and nephro­ structures and of the whole body, and in magnetic genic systemic fibrosis: update. Can Adverse React News 2007; 17 (4): 1-2. Reviews. Also available at: http://www.hc-sc.gc.ca/dhp-mps/alt_fonnats/hpfb­ resonance angiography. 1. Runge VM, Parker JR. Worldwide clinical safety assessment of dgpsa/pdf/medeff/carn-bceLvl7n4-eng.pdf (accessed 25/08110) Gadoteric acid is given intravenously as the meglumine gadoteridol injection: an update. Bur Radiol l997; 7 (suppl 5): 243-5. 3. Mareno-Romero JA, et al. Nephrogenic systemic fibrosis: a case series salt. It is available as a solution containing meglumine suggesting gadolinium as a possible aetiological factor. Br J Dermatol gadoterate 376.9mg/mL (0.5 mmol/mL). The usual dose in Hypersensitivity. For a report of an anaphylactoid reaction 2007; 157: 783-7. 4. Penfield JG, Reilly RF. Nephrogenic systemic fibrosis risk: is there a adults and children is 0.2 mL/kg (0.1 mmol/kg) by with gadoteridol, see under Adverse Effects of Gadopente­ difference between gadolinium-based contrast agents? Semin Dial 200B; intravenous injection. A second dose of up to 0.4 mL/kg tic Acid, p. 1586.2. 21: 129-34. (0.2 mmol/kg) may be given within 30 minutes if necessary. 5. FDA. Gadolinium-containing contrast agents for magnetic resonance For angiography, a dose of 0.1 to 0.2 mL/kg (0.05 to imaging (MRI): Omniscan, OptiMARK, Magnevist, ProHance, and Pharmacokinetics MultiHance (issued 8th June 2006, updated 22nd December, 2006 and 0.1 mmol/kg) may be given, repeated if required. 23rd May, 2007). Available at: http://www.fda.gov/Drugs/DrugSafety/ Gadoteridol is distributed into extracellular fluid after PostmarketDrugSafetylnformationforPatientsandProviders/ intravenous injection. About 94% of a dose is excreted Administration in children. For doses of gadoteric add in ucml42884.htm (accessed 24/08/IO) unchanged in the urine within 24 hours. An elimination children, see Uses and Administration, above. 6. MHRA/CHM. Gadolinium-containing MRI contrast agents: nephrogenic half-life of about 1.57 hours has been reported. systemic fibrosis. Drug Safety Update 2007; 1 (I): 2-3. Available at: http:// www.mhra.gov.uk/home/idcplg?IdcService=GET_Fll.E&dDocName=­ CON203180l&RevisionSelectionMethod=LatestReleased (accessed Adverse Effects and Precautions r ti . .. 14/07/08) �r.�J?.?. �. ��� ................................ ............ ................ ............ 7. Health Canada. Association of nephrogenic systemic fibrosis/nephro­ As for Gadopentetic Add, p. 1586.2. Praprietary Preparations (details are given in Volume B) genic fibrosing dermopathy (NSF/NFD) with the use of gadolinium­ containing contrast agents (issued 9th March, 2007). Available at: Single-ingredient Preparations. Austral. : Prohance; Austria: Pro· http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/medeff/ Hypersensitivity. For reports of anaphylactoid reactions hance; Belg.: Prohance; Canad. : ProHance; Cz.: Prohance; gadolinium_nth-aah-eng.pdf (accessed 18/03/09) with gadoterate, see under Adverse Effects of Gadopentetic Denm.: Prohance; Fin.: Prohance; Fr.: Prohance; Ger. : Pro­ 8. Adverse Drug Reactions Advisory Committee (ADRAC). MRI scans with Acid, p. 1586.2. hance; Irl. : Probance; Ita!. : Prohance; Jp n: Prohance; Neth.: gadolinium-containing contrast agents and the risk of nephrogenic systemic fibrosis-caution in patients with renal impairment. Aust Prohance; Norw.: Prohance; Spain: Prohance; Swed.: Prohance; Adverse Drug Read Bull 2008; 17: 2. Also available at: http://www.tga. Switz. : Prohance; UK: Prohance; USA: Prohance. health.gov.au/adr/aadrb/aadr0802.pdf (accessed 18/03/09) Pharmacokinetics 9. MHRA/CHM. Gadolinium-containing contrast agents: new advice to Phannacopaeial Preparations minimise the risk of nephrogenic systemic fibrosis. Drug Safety Update Gadoterate is distributed into the extracellular space after USP 36: Gadoteridol Injection. 2010; 3 (6): 3-5. Available at: http:/lwww.mhra.gov.uk/Publications/ intravenous injection. It is not bound to plasma proteins. A Safetyguidance/DrugSafetyUpdate/CON068297 (accessed 22/03/10) plasma half-life of about 1.5 hours has been reported. It is not metabolised and about 90% of a dose is excreted in the Gadoversetamide (BAN. USAN, r!NNJ Pharmacokinetics urine within 24 hours. Gadopentetate is rapidly distributed into the extracellular space after intravenous injection. An elimination half-life of �.��J?.�.�<J.Ii��� .................................. ........................ ................. 1.6 hours has been reported. It is not metabolised and about Proprietary Preparations (details are given in Volume B) 90% of a dose is excreted in the urine within 24 hours. It does not appear to bind to plasma proteins. A small amount Single-ingredient Preparations. Arg. : Dotarem; Austral. : Dotar· is distributed into breast milk. Gadopentetate is removed by em; Austria: Artirem; Dotarem; Belg.: Artirem; Dotarem; Chile: haemodialysis. Dotarem; Cz. : Dotarem; Denm.: Dotarem; Fin.: Dotarem; Fr. : Artirem; Dotarem; Ger.: Artirem; Dotarem; Gr.: Dotarem; Hung.: Dotarem; Irl. : Dotarem; Israel: Dotarem; Ital. : Dotarem; �.��!?.�.��!����············································································ Neth.: Artirem; Dotarem; Norw. : Dotarem; NZ: Dotarem; Port.: Proprietary Preparations (details are given in Volume B) Dotarem; Rus.: Dotarem (,[{oTapeM); Spain: Dotarem; Swed.: Pharmacopoeias. In us. Dotarem; Switz. : Artirem; Dotarem; Thai. : Dotarem; Turk. : USP 36: Single-ingredient Preparations. Arg. : Magnevist; Opadte; View­ (Gadoversetamide). A white odourless powder. USA: Venez. : gam; Austral. : Magnevist; Austria: Magnegita; Magnevist; Dotarem; Dotarem; Dotarem. Freely soluble in water. Store.in airtight containers. Protect Belg.: Magnegita; Magnevist; Braz. : Magnevistan; Canad. : from light. Magnevist; Chile: Magnevistant; Cz. : Magnegita; Magnetolux; Magnevist; Denm.: Magnegitat; Magnevist; Magnograf; Fin.: Gadoteridol (BAN, USAN, riNNJ Uses and Administration Magnevist; Fr.: Magnegita; Magnevist; Ger.: Magnegita; Mag­ nevist; MR-Lux; Gr.: Magnevist; Hung.: Magnevist; India: Gadoversetamide is a nonionic gadolinium chelate with Magnevist; Irl. : Magnegita; Magnetolux; Magnevist; Israel: actions and uses similar to those of gadopentetic acid Gado-MRI; Magneto!; Ital. : Magnevist; Mex. : Viewgamt; Neth.: (p. 1586.1). It has paramagnetic properties and is used as a Magnegita; Magnevistt; Magnograft; Norw.: Magnevist; NZ: magnetic resonance contrast medium (p. 1580.1). It Magnevist; Philipp. : Gadomin; Port.: Ceacont; Magnegita; distributes mainly into extracellular fluid, but does not Magnevist; Rus.: Magnevist (Marnesucr); S.Afr. : Magnevist; cross the blood-brain barrier, and is used in imaging of Spain: Magnetolux; Magnevist; Magnograft; Swed.: Magnevist; cranial and spinal structures and of the whole body Switz.: Magnevist; Magnograf; MR-Lux; Turk.: Magnevist; UK: (particularly to visualise the liver). Magnevist; Ukr.: Magnilek (MarnUJieK); Tomovist (ToMOBHCT); Gadoversetamide is available as a solution containing USA: Magnevist; Venez. : Magnevistan. 330.9mg/mL (0.5 mmol/mL). The usual dose is 0.2 mL/kg Pharmacopoeial Preparations (0.1 mmol/kg) intravenously. USP 36: Gadopentetate Dimeglumine Injection. USP 36: (Gadoteridol). A white to off-white, odourless, crystalline powder. Freely soluble in water and in methyl Adverse Effects and Precautions alcohol; soluble in isopropyl alcohol. Store in airtight As for Gadopentetic Acid, p. 1586.2. containers. Protect from light. Interference with diagnostic tests. Like gadodiamide (see Uses and Administration p. 1585.3), gadoversetarnide may interfere with colori­ metric methods for measuring serum-calcium concentra­ Gadoteridol is a nonionic gadolinium chelate with actions tions. and uses similar to those of gadopentetic add (p. 1586.1). It Gadoversetamide may also interfere with measurement has paramagnetic properties and is used as a magnetic of serum-copper, iron, and zinc concentrations. resonance contrast medium (p. 1580.1). It distributes mainly into extracellular fluid, but does not cross the blood­ Renal impairment. For the view that gadoversetamide brain barrier, and is used in bnaging of cranial and spinal may carry an increased risk of the development of nephro­ structures and of the whole body. genic systemic fibrosis in patients with renal impainnent, Gadoteridol is available as a solution containing see p. 1586.3. 279.3 mg/mL (0.5 mmol/mL). The usual adult dose is 0.2 mL/kg (0.1 mmol/kg) intravenously; for CNS imaging, an additional dose of up to 0.4mL/kg (0.2 mmol/kg) may be Pharmacokinetics given up to 30 minutes after the first if necessary. A single Gadoversetamide is distributed into the extracellular space dose of 0.2 mL/kg (0.1 mmol/kg) is used in children from 6 after intravenous injection. It is not bound to plasma months of age (see also below).
Load more

Recommended publications
  • ACR Manual on Contrast Media
    ACR Manual On Contrast Media 2021 ACR Committee on Drugs and Contrast Media Preface 2 ACR Manual on Contrast Media 2021 ACR Committee on Drugs and Contrast Media © Copyright 2021 American College of Radiology ISBN: 978-1-55903-012-0 TABLE OF CONTENTS Topic Page 1. Preface 1 2. Version History 2 3. Introduction 4 4. Patient Selection and Preparation Strategies Before Contrast 5 Medium Administration 5. Fasting Prior to Intravascular Contrast Media Administration 14 6. Safe Injection of Contrast Media 15 7. Extravasation of Contrast Media 18 8. Allergic-Like And Physiologic Reactions to Intravascular 22 Iodinated Contrast Media 9. Contrast Media Warming 29 10. Contrast-Associated Acute Kidney Injury and Contrast 33 Induced Acute Kidney Injury in Adults 11. Metformin 45 12. Contrast Media in Children 48 13. Gastrointestinal (GI) Contrast Media in Adults: Indications and 57 Guidelines 14. ACR–ASNR Position Statement On the Use of Gadolinium 78 Contrast Agents 15. Adverse Reactions To Gadolinium-Based Contrast Media 79 16. Nephrogenic Systemic Fibrosis (NSF) 83 17. Ultrasound Contrast Media 92 18. Treatment of Contrast Reactions 95 19. Administration of Contrast Media to Pregnant or Potentially 97 Pregnant Patients 20. Administration of Contrast Media to Women Who are Breast- 101 Feeding Table 1 – Categories Of Acute Reactions 103 Table 2 – Treatment Of Acute Reactions To Contrast Media In 105 Children Table 3 – Management Of Acute Reactions To Contrast Media In 114 Adults Table 4 – Equipment For Contrast Reaction Kits In Radiology 122 Appendix A – Contrast Media Specifications 124 PREFACE This edition of the ACR Manual on Contrast Media replaces all earlier editions.
    [Show full text]
  • Gadolinium Based Contrast Agents
    CE Credits Available CONSIDERATIONS IN THE SELECTION OF A NEW GADOLINIUM-BASED CONTRAST AGENT SUPPLEMENT TO MAY 2014 THE JOURNAL OF PRACTICAL MEDICAL IMAGING AND MANAGEMENT Considerations in the Selection of a New Gadolinium-Based Contrast Agent Michael F. Tweedle, PhD Emanuel Kanal, MD, FACR, FISMRM Robert Muller, PhD Stefanie Spielman Professor of Radiology Professor of Radiology and Neuroradiology Department of General, Organic & The Ohio State University University of Pittsburgh Medical Center Biochemical Chemistry Columbus, OH Pittsburgh, PA University of Mons Mons, Belgium Supported by an unrestricted educational grant from © May 2014 www.appliedradiology.com SUPPLEMENT TO APPLIED RADIOLOGY n 1 Publisher Kieran Anderson Executive Editor Cristen Bolan Art and Production Barbara A. Shopiro Applied Radiology and this supplement, Considerations in the Selection of a New Gadolinium-Based Contrast Agent, are published by Anderson Publishing, Ltd. The journal does not warrant the expertise of any author in a particular field, nor is it responsible for any statements by such authors. The opinions expressed in this supplement are those of the authors. They do not imply endorsement of advertised products and do not necessarily reflect the opinions or recommendations of our sponsors or the editors and staff of Applied Radiology. Copyright © 2014 by Anderson Publishing, Ltd., 180 Glenside Avenue, Scotch Plains, NJ 07076 All rights reserved. Cover images courtesy of Howard A. Rowley, MD. Considerations in the Selection of a New Gadolinium-Based Contrast Agent Our 3 esteemed faculty summarize the similarities and differences among the gadolinium-based contrast agents (GBCAs) currently utilized for magnetic resonance imaging (MRI), with emphasis on stability and relaxivity.
    [Show full text]
  • DISSERTATION INVESTIGATION of CATIONIC CONTRAST-ENHANCED COMPUTED TOMOGRAPHY for the EVALUATION of EQUINE ARTICULAR CARTILAGE Su
    DISSERTATION INVESTIGATION OF CATIONIC CONTRAST-ENHANCED COMPUTED TOMOGRAPHY FOR THE EVALUATION OF EQUINE ARTICULAR CARTILAGE Submitted by Bradley B. Nelson Department of Clinical Sciences In partial fulfillment of the requirements For the Degree of Doctor of Philosophy Colorado State University Fort Collins, Colorado Fall 2017 Doctoral Committee: Advisor: Christopher E. Kawcak Co-Advisor: Laurie R. Goodrich C. Wayne McIlwraith Mark W. Grinstaff Myra F. Barrett Copyright by Bradley Bernard Nelson 2017 All Rights Reserved ABSTRACT INVESTIGATION OF CATIONIC CONTRAST-ENHANCED COMPUTED TOMOGRAPHY FOR THE EVALUATION OF EQUINE ARTICULAR CARTILAGE Osteoarthritis and articular cartilage injury are substantial problems in horses causing joint pain, lameness and decreased athleticism resonant of the afflictions that occur in humans. This debilitating joint disease causes progressive articular cartilage degeneration and coupled with a poor capacity to heal necessitates that articular cartilage injury is detected early before irreparable damage ensues. The use of diagnostic imaging is critical to identify and characterize articular cartilage injury, though currently available methods are unable to identify these early degenerative changes. Cationic contrast-enhanced computed tomography (CECT) uses a cationic contrast media (CA4+) to detect the early molecular changes that occur in the extracellular matrix. Glycosaminoglycans (GAGs) within the extracellular matrix are important for the providing the compressive stiffness of articular cartilage and their degradation is an early event in the development of osteoarthritis. Cationic CECT imaging capitalizes on the electrostatic attraction between CA4+ and GAGs; exposing the proportional relationship between the amount of GAGs present within and the amount of CA4+ that diffuses into the tissue. The amount of CA4+ that resides in the tissue is then quantified through CECT imaging and estimates tissue integrity through nondestructive assessment.
    [Show full text]
  • Advisory Committee Briefing Document Medical Imaging Drugs Advisory Committee (MIDAC) September 8, 2017
    Dotarem® (gadoterate meglumine) Injection – NDA# 204781 Advisory Committee Optimark® (gadoversetamide) Injection - NDAs# 020937, 020975 & 020976 Briefing Document Advisory Committee Briefing Document Medical Imaging Drugs Advisory Committee (MIDAC) September 8, 2017 DOTAREM® (gadoterate meglumine) Injection NDA 204781 Guerbet LLC, 821 Alexander Rd, Princeton, NJ 08540 OPTIMARK® (gadoversetamide) Injection NDAs 020937, 020975 & 020976 Liebel-Flarsheim Company LLC, 1034 Brentwood Blvd., Richmond Heights, MO 63117 ADVISORY COMMITTEE BRIEFING MATERIALS AVAILABLE FOR PUBLIC RELEASE Information provided within this briefing document is based upon medical and scientific information available to date. ADVISORY COMMITTEE BRIEFING MATERIALS AVAILABLE FOR PUBLIC RELEASE Page 1 / 168 Dotarem® (gadoterate meglumine) Injection – NDA# 204781 Advisory Committee Optimark® (gadoversetamide) Injection - NDAs# 020937, 020975 & 020976 Briefing Document EXECUTIVE SUMMARY Gadolinium-based contrast agents (GdCAs) are essential for use in magnetic resonance imaging (MRI). Although non-contrast-enhanced MRI may be sufficient for use in some clinical conditions, contrast-enhanced MRI (CE-MRI) using GdCA provides additional vital diagnostic information in a number of diseases. It is widely recognized that CE-MRI increases diagnostic accuracy and confidence, and thus can impact the medical and/or surgical management of patients. Based on the chemical structure of the complexing ligand, GdCA are classified as linear (L-GdCA) or macrocyclic (M-GdCA) and can be ionic or nonionic and those characteristics have a dramatic influence on the stability of the GdCA. Dotarem®, a M-GdCA, was first approved in France in 1989. US-FDA approval was obtained in March 2013 for “intravenous use with MRI of the brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity”, at the dose of 0.1 mmol/kg BW.
    [Show full text]
  • Gadoversetamide (BAN, USAN, Rinn) Is Excreted in the Urine Within 24 Hours
    1480 Contrast Media gadolinium-containing contrast media should be restricted in pa- Gadoteric Acid (BAN, rINN) Adverse Effects and Precautions tients with severe renal impairment (GFR less than Acide Gadotérique; Ácido gadotérico; Acidum Gadotericum; As for Gadopentetic Acid, above. 30 mL/minute per 1.73 m2). The MHRA contra-indicates the use Gadoteerihappo; Gadotersyra; Gd-DOTA; ZK-112004. Hydro- ◊ Reviews. of gadodiamide or gadopentetate in such patients (other gadolin- ium-containing contrast media are under review), whereas the gen [1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraaceto(4−)]- 1. Runge VM, Parker JR. Worldwide clinical safety assessment of gadoteridol injection: an update. Eur Radiol 1997; 7 (suppl 5): FDA advises that all gadolinium-containing contrast media gadolinate(1−); Hydrogen [1,4,7,10-tetrakis(carboxylatomethyl)- 4 243–5. should be avoided unless the diagnostic information is essential 1,4,7,10-tetra-azacyclododecane-κ N]gadolinate(1−). and cannot be obtained another way. The FDA gives a similar Гадотеровая Кислота Hypersensitivity. For a report of an anaphylactoid reaction with gadoteridol, see under Adverse Effects of Gadopentetic Ac- warning for use in patients with acute renal failure associated C16H25GdN4O8 = 558.6. with hepato-renal syndrome or around the time of liver trans- CAS — 72573-82-1. id, p.1479. plantation. The value of haemodialysis to remove gadolinium- ATC — V08CA02. Pharmacokinetics containing contrast media after use is unknown. ATC Vet — QV08CA02. Gadoteridol is distributed into extracellular fluid after intrave- 1. Perazella MA, Rodby RA. Gadolinium-induced nephrogenic nous injection. About 94% of a dose is excreted unchanged in the systemic fibrosis in patients with kidney disease.
    [Show full text]
  • Injection of Contrast Media V7 – 2010 13 5
    ACR Manual on Contrast Media Version 8 2012 ACR Committee on Drugs and Contrast Media ACR Manual on Contrast Media Version 8 2012 ACR Committee on Drugs and Contrast Media © Copyright 2012 American College of Radiology ISBN: 978-1-55903-009-0 Table of Contents Topic Last Updated Page 1. Preface. V8 – 2012 . 3 2. Introduction . V7 – 2010 . 4 3. Patient Selection and Preparation Strategies . V7 – 2010 . 5 4. Injection of Contrast Media . V7 – 2010 . 13 5. Extravasation of Contrast Media . V7 – 2010 . 17 6. Adverse Events After Intravascular Iodinated Contrast Media . V8 – 2012 . 21 Administration 7. Contrast Media Warming . V8 – 2012 . 29 8. Contrast-Induced Nephrotoxicity . V8 – 2012 . 33 9. Metformin . V7 – 2010 . 43 10. Contrast Media in Children . V7 – 2010 . 47 11. Iodinated Gastrointestinal Contrast Media in Adults: Indications . V7 – 2010 . 55 and Guidelines 12. Adverse Reactions to Gadolinium-Based Contrast Media . V7 – 2010 . 59 13. Nephrogenic Systemic Fibrosis (NSF) . V8 – 2012 . 63 14. Treatment of Contrast Reactions . V8 – 2012 . 73 15. Administration of Contrast Media to Pregnant or Potentially . V6 – 2008. 75 Pregnant Patients 16. Administration of Contrast Media to Breast-Feeding Mothers . V6 – 2008 . 79 Table 1 – Indications for Use of Iodinated Contrast Media . V6 – 2008 . 81 Table 2 – Organ or System-Specific Adverse Effects from the Administration . V7 – 2010 . 82 of Iodine-Based or Gadolinium-Based Contrast Agents Table 3 – Categories of Reactions . V7 – 2010 . 83 Table 4 – Management of Acute Reactions in Children . V7 – 2010 . 84 Table 5 – Management of Acute Reactions in Adults . V6 – 2008 . 86 Table 6 – Equipment for Emergency Carts . V6 – 2008 .
    [Show full text]
  • Guideline on the Use of Gadolinium-Containing MRI Contrast Agents in Patients with Renal Impairment
    Guideline on the use of Gadolinium-containing MRI Contrast Agents in Patients with Renal Impairment The Royal Australian and New Zealand College of Radiologists® Guideline on the use of Gadolinium-containing MRI Contrast Agents in Patients with Renal Impairment Clinical Radiology Guideline Name of document and version: Guideline on the use of Gadolinium-containing MRI Contrast Agents in Patients with Renal Impairment, Version 3 Approved by: Faculty of Clinical Radiology Council Date of approval: 21 November 2019 ABN 37 000 029 863 Copyright for this publication rests with The Royal Australian and New Zealand College of Radiologists ® The Royal Australian and New Zealand College of Radiologists Level 9, 51 Druitt Street Sydney NSW 2000 Australia New Zealand Office: Floor 6, 142 Lambton Quay, Wellington 6011, New Zealand Email: [email protected] Website: www.ranzcr.com Telephone: +61 2 9268 9777 Disclaimer: The information provided in this document is of a general nature only and is not intended as a substitute for medical or legal advice. It is designed to support, not replace, the relationship that exists between a patient and his/her doctor. TABLE OF CONTENTS 1. Introduction 4 2. Nephrogenic Systemic Fibrosis 4 3. Recommendations 7 4. Further Information 10 5. Related documents 10 6. Acknowledgements 10 7. Appendices 10 8. References and Bibiolography 10 Page 2 of 14 About the College The Royal Australian and New Zealand College of Radiologists (RANZCR) is a not-for-profit association of members who deliver skills, knowledge, insight, time and commit to promoting the science and practice of the medical specialties of clinical radiology (diagnostic and interventional) and radiation oncology in Australia and New Zealand.
    [Show full text]
  • Active Moiety Name FDA Established Pharmacologic Class (EPC) Text
    FDA Established Pharmacologic Class (EPC) Text Phrase PLR regulations require that the following statement is included in the Highlights Indications and Usage heading if a drug is a member of an EPC [see 21 CFR 201.57(a)(6)]: Active Moiety Name “(Drug) is a (FDA EPC Text Phrase) indicated for [indication(s)].” For each listed active moiety, the associated FDA EPC text phrase is included in this document. For more information about how FDA determines the EPC Text Phrase, see the 2009 "Determining EPC for Use in the Highlights" guidance and 2013 "Determining EPC for Use in the Highlights" MAPP 7400.13.
    [Show full text]
  • Application for Inclusion of Gadolinium-Based Contrast Agents to the WHO
    Application for inclusion of Gadolinium‐based contrast agents to the WHO Essential List of Medicines Submitted by Daniel Patiño, PhD (McMaster) Faculty of Medicine University of Antioquia, Medellin, Colombia Holger J. Schünemann, MD, PhD Chair and Professor, Departments of Clinical Epidemiology and Biostatistics Co‐Director, WHO Collaborating Center for Evidence Informed Policy, McMaster University Potential conflicts of interest Dr. Patiño and Dr. Schünemann declare that they have no COI. Date: Dec 15, 2014 1 Application to add Gadolinium‐based contrast agents to the WHO Essential List of Medicines 1. Summary statement of the proposal for inclusion, change or deletion Currently the 18th edition of WHO Model List of Essential Medicines does not include gadolinium‐based contrast agents (Gd‐CAs) under 14.2 radio contrast media classification. Since the introduction of gadopentate dimeglumine in 1988, gadolinium‐based contrast agents have significantly improved the diagnostic efficacy of Magnetic Resonance Image (MRI) (1). Gadolinium‐based contrast agents are intravenous agents used for contrast enhancement with magnetic resonance imaging (MRI) and with magnetic resonance angiography (MRA). The Gd‐CAs are available for different types of MR scan varying from product to product, including liver, brain and whole body scan. This application proposes to add Gd‐CAs for the complementary list of WHO Essential List of Medicines to be used in the detection of lymph node metastases. It will focus on the following ‘general purpose’ Gd‐CAs: gaodopentate dimeglumine, gadodiamide, gadoversetamide, gadobenate dimeglumine, gadoteridol, gadoteric acid, gadobutrol. We will not include the ‘newer’ Gd‐CAs that are organ specific like the hepatobiliary‐specific contrast agents that are available for imaging the liver (e.g., gadoxetic acid).
    [Show full text]
  • Environmentally Classified Pharmaceuticals 2014-2015
    2014-2015 ENVIRONMENTALLY CLASSIFIED PHARMACEUTICALS Stockholm County Council Contents Reducing Residues from Pharmaceuticals in Nature is Part Reducing Residues from Pharmaceuticals of the Environmental Work of in Nature is Part of the Environmental Work of Stockholm County Council ..................1 Stockholm County Council Impact of Pharmaceuticals on Contributing to the reduction of environmental the Environment .........................................................................2 risks from pharmaceuticals is an important part How the Substances are Classified ......................2 of the environmental work of Stockholm County How to Read the Table .................................................4 Council. According to the Environmental Challenge Substances which are Exempt 2016, the Council´s 2012-2016 Environmental from Classification ............................................................6 Programme, the Council is mandated to i.a. do The Precautionary Principle ......................................6 preventive environmental health work. This invol- Tables A Alimentary Tract and Metabolism............................7 ves fostering healthy inhabitants in an environ- ment with clean air and water. To reduce the most B Blood and Blood-Forming Organs ............................9 environmentally hazardous remains of medicinal C Cardiovascular System .................................................10 products in the natural surroundings is therefore D Dermatologicals ............................................................13
    [Show full text]
  • Gadavist (Gadobutrol) Injection, for Intravenous Use ------DOSAGE FORMS and STRENGTHS------Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION The recommended dose of Gadavist is 0.1 mL/kg body weight (0.1 mmol/kg), administered as an intravenous bolus injection at a flow rate of approximately These highlights do not include all the information needed to use 2 mL/second. Flush the intravenous cannula with physiological saline solution Gadavist safely and effectively. See full prescribing information for after the injection. (2) Gadavist. Gadavist (gadobutrol) injection, for intravenous use ---------------------DOSAGE FORMS AND STRENGTHS---------------------- Initial U.S. Approval: 2011 Gadavist injection contains 1 mmol gadobutrol/mL (equivalent to 604.72 mg gadobutrol/mL) and is available in vials and prefilled syringes (3) WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF) See full prescribing information for complete boxed warning -------------------------------CONTRAINDICATIONS------------------------------ Gadolinium-based contrast agents (GBCAs) increase the risk for NSF None (4) among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. -----------------------WARNINGS AND PRECAUTIONS------------------------ • The risk for NSF appears highest among patients with: • Nephrogenic Systemic Fibrosis has occurred in patients with impaired o Chronic, severe kidney disease (GFR < 30 mL/min/1.73m2), or elimination of GBCAs. Higher than recommended dosing or repeated o Acute kidney injury. dosing appears to increase the risk. (5.1) • Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically • Hypersensitivity: Anaphylactoid/anaphylactic reactions with reduced renal function (for example, age >60 years, hypertension or cardiovascular, respiratory or cutaneous manifestations, ranging from diabetes), estimate the glomerular filtration rate (GFR) through mild to severe, including death, have uncommonly occurred.
    [Show full text]
  • (PRAC) Der European Medicines Agency (EMA) Bezüglich Gadoliniumhaltiger MR- Kontrastmittel: Was Bedeutet Dies Für Die Radiologen in Der Schweiz?
    Pressemitteilung des Pharmacovigilance Risk Assessment Committee (PRAC) der European Medicines Agency (EMA) bezüglich gadoliniumhaltiger MR- Kontrastmittel: Was bedeutet dies für die Radiologen in der Schweiz? In der Pressemitteilung des Pharmacovigilance Risk Assessment Committee (PRAC) vom 10. März 2017 (siehe Seite 2) wird empfohlen vier lineare MR Kontrastmittel ‚vom europäischen Markt‘ zu nehmen. Hierbei handelt es sich um folgende Produkte: Wirkstoff Handelsname Hersteller Gadobensäure Multihance Bracco Gadodiamid Omniscan GE Healthcare Gadopentetsäure Magnograf Berlis Gadoversetamid Optimark Mallinckrodt Gadoversetamid (Optimark) ist in der Schweiz nicht verfügbar, sodass letztendlich die drei Kontrastmittel Gadobensäure (Multihance), Gadodiamid (Omniscan) und Gadopentetsäure (Magnograf) verbleiben. Bei letzterem ist zu sagen, dass dies lediglich die intravenöse Applikation betrifft; die intraartikuläre Applikation von Gadopentetsäure (Magnevist® 2 mmol/l Injektionslsg) ist von dieser Empfehlung ausgenommen, da nach Ansicht der Kommission die Vorteile die potentiellen Nachteile überwiegen. Das gleiche gilt für Gadoxetsäure (Primovist), ebenfalls ein lineares MR-Kontrastmittel: auch hier ist das PRAC der Meinung, dass die Vorteile die potentiellen Nachteile überwiegen. Vorerst (Zeitpunkt: 10.03.2017) ist es nur eine Empfehlung, die das Pharmacovigilance Risk Assessment Committee (PRAC) ausgesprochen hat. Diese Empfehlung geht nun an das Committee for Medicinal Products for Human Use (CHMP), welches vermutlich die Empfehlung des
    [Show full text]